This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...